Omar 2025 — Soluble CTLA-4 and CD80 explain 55-58% of variance in chronic fatigue + depression + anxiety in preeclampsia (H5 CTLA4 axis evidence)

One-paragraph summary

Case-control study of n=90 preeclampsia (PE) + n=60 non-PE pregnant controls. Measured soluble CD80 (sCD80), soluble cytotoxic T-lymphocyte antigen-4 (sCTLA-4), vitamin D, GM-CSF, zinc, copper, magnesium, calcium. Outcome measures: Hamilton Depression (HAMD), Anxiety (HAMA), and Fibro-Fatigue (FF) rating scales. Findings: PE women show elevated sCTLA-4, sCD80, copper; reduced zinc, magnesium, calcium. Multiple regression: 55.8-58.0% of variance in HAMD/HAMA/FF scores explained by serum biomarkers — top three: sCTLA-4, sCD80, vitamin D. The sCTLA-4/sCD80 ratio significantly inversely associated with HAMD/HAMA/FF scores. The Fibro-Fatigue scale is a 1990s instrument originally developed for ME/CFS+FM symptom domain measurement — its inclusion makes this paper directly relevant to FM phenotype variance explained by immune-checkpoint biomarkers. First clinical evidence that soluble CTLA-4 is involved in chronic-fatigue + depression + anxiety pathophysiology, supporting the H5 framework's CTLA4 axis and providing a candidate biomarker for Q-Gen-6 (abatacept stratification).

Claims as triples

• soluble_CTLA4 — elevated_in → preeclampsia [evidence: case-control n=90+60; confidence: emerging]
• soluble_CD80 — elevated_in → preeclampsia [evidence: same study; confidence: emerging]
• soluble_CTLA4 — explains_variance → fibro_fatigue_score [evidence: multiple regression top biomarker; confidence: emerging]
• soluble_CTLA4 — explains_variance → depression_score [evidence: same regression; confidence: emerging]
• sCTLA4_sCD80_ratio — inversely_correlates → fibro_fatigue_score [evidence: same study; confidence: emerging]
• immune_checkpoint_dysregulation — drives → chronic_fatigue_phenotype [evidence: framework consolidation; confidence: emerging]

Methods note

Case-control with appropriate biomarker panel + standard psychometric scales (HAMD, HAMA, FF). Multiple regression for variance explanation. ELISA-based soluble-protein measurement. PE population means the findings are PE-specific at primary tier; cross-condition extrapolation to FM/ME/CFS is project-driven inference. Maes group (Maes M is senior author) has extensive prior chronic-fatigue + immune-biomarker literature — this paper is in their established line of work on chronic-fatigue immunology.

Limitations

• PE population, not FM or ME/CFS directly
• Cross-sectional; no longitudinal follow-up
• The Fibro-Fatigue scale was the only FM-relevant outcome measure; FM diagnosis not directly assessed
• Soluble immune-checkpoint levels reflect ongoing immune activation rather than CTLA4 risk-allele carriage — the H5 framework's CTLA4 genetic risk and the soluble-checkpoint phenotype may or may not correlate
• 55-58% variance explanation is substantial but the regression includes vitamin D, zinc, magnesium, calcium as covariates; the CTLA-4-specific contribution is one of three top biomarkers

Open questions raised

• Q-Gen-18 (new): Is serum sCTLA-4 elevated in FM patients vs healthy controls? Adding sCTLA-4 ELISA to existing FM cohort serum biobanks is low-cost. The Fibro-Fatigue scale + sCTLA-4 correlation prediction in FM patients directly extends Omar 2025.
• Q-Gen-19 (new): Does sCTLA-4 in FM patients discriminate FM-IgG-positive vs FM-IgG-negative subsets? Would partially close B-Gen-1 if sCTLA-4 enriches in the IgG-positive subset.
• Q-Gen-20 (new): Is the sCTLA-4/sCD80 ratio a candidate stratifier for abatacept (Q-Gen-6) response? The inverse-correlation with FF score suggests low ratio = high FF score = high baseline T-cell activation = candidate abatacept-responsive phenotype.

Triangulation notes

• Adds clinical patient evidence to the H5 CTLA4 arm: H5 framework proposed CTLA4 risk variants as part of the tolerance-failure triad; Omar 2025 shows that the soluble form of CTLA-4 is elevated in a chronic-fatigue phenotype (FF score). The two are complementary — risk-allele carriage (heritable) + soluble-CTLA-4 elevation (state biomarker).
• Maes group context: this is one of multiple papers from the Maes / Al-Hakeim / Moustafa group on immune-checkpoint and chronic-fatigue. Future ingestion should look for related Maes-group papers on sCD28, sPD-1, sPD-L1, soluble immune-checkpoint panels in ME/CFS / FM specifically.
• Compatible with the CTLA-4 + abatacept cure-path arm: the inverse sCTLA-4/sCD80 ratio correlation with FF score predicts abatacept (CTLA-4-Ig — exogenous CTLA-4 coinhibitory signal) should reduce FF score in low-ratio patients. Direct translation pathway.
• Connects to Bahraini MS SARAF/STIM1/ORAI1 paper (also accepted in this batch): both papers establish patient-cohort biomarkers in their respective H5/H5b axes. Together they validate the broader "measurable peripheral biomarker" framing for both H5 (sCTLA-4) and H5b (SARAF) arms.

Bridges

• B-Gen-1 advance: provides patient-cohort evidence for soluble immune-checkpoint involvement in chronic-fatigue phenotype. The H5 CTLA4 arm gains a measurable biomarker.
• Q-Gen-6 / abatacept cure-path arm refinement: sCTLA-4/sCD80 ratio becomes candidate stratifier for abatacept response.

Ontology additions needed

• Add soluble_CTLA4 as new biomarker entity
• Add soluble_CD80 as new biomarker entity
• Add sCTLA4_sCD80_ratio as composite biomarker
• Add fibro_fatigue_scale_score as outcome measure (may already exist)
• Consider adding preeclampsia as new cross-condition comorbidity
• Consider adding chronic_fatigue_phenotype as composite-symptom entity (FM/ME/CFS-shared)

Chain-map update

• H5 CTLA4 arm: gains patient-cohort biomarker evidence (sCTLA-4 in chronic-fatigue phenotype). The H5 framework's immune-checkpoint axis moves from "predicted by genetic risk" toward "measurable in serum."
• Cure-path-arm stratification: abatacept (Q-Gen-6) now has a candidate biomarker (sCTLA-4/sCD80 ratio) for patient selection.

Confidence-tier framing

• sCTLA-4 elevated in preeclampsia chronic-fatigue: emerging (single cohort, novel finding)
• sCTLA-4 explains variance in FF/HAMD/HAMA scores: emerging
• sCTLA-4/sCD80 ratio as biomarker: emerging-with-replication-needed
• Same finding in FM: inferred (predicted by framework; not tested)
• Q-Gen-6 / abatacept stratifier: inferred